AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21359953
Drug: Lapatinib 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1,000 mg/day and nab-paclitaxel 260 mg/m2 every 3 weeks for four cycles
Trial: 21366812
Drug: G-allele of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-allele of rs10830963
Trial: 21367942
Drug: Serum potassium
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum potassium concentrations <4.0 mEq/L
Trial: 21367942
Drug: Serum potassium
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum potassium concentrations 4.0-4.4 mEq/L
Trial: 21367942
Drug: Serum potassium
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum potassium concentrations 4.5-4.9 mEq/L
Trial: 21371308
Drug: Extracorporeal plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal plasma treatment with a granulocyte bioreactor, treated twice within 72 hours for a mean of 342 ± 64 minutes/treatment with 1.41 ± 0.43 × 10E10 granulocytes from healthy donors.
Trial: 21371308
Drug: Extracorporeal plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal plasma treatment with a granulocyte bioreactor
Trial: 21372218
Drug: E7080 13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7080 13 mg bid
Trial: 21372302
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day simvastatin
Trial: 21372302
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day simvastatin
Trial: 21372302
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day simvastatin (48 hours after admission)
Trial: 21372302
Drug: Early statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early statin treatment
Trial: 21372302
Drug: Higher statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher statin doses
Trial: 21377509
Drug: H6N1 influenza
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H6N1 influenza virus vaccine (10^7 TCID(50), 2 doses)
Trial: 21377509
Drug: H6N1 influenza
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H6N1 influenza virus vaccine (2 doses)
Trial: 21377994
Drug: Romidepsin at
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin at a dosage of 13.3 mg/m(2)/day on days 1, 8, and 15 of each 28-day cycle (phase II component)
Trial: 21377994
Drug: Romidepsin at
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin at a dosage of 17.7 mg/m(2)/d (phase I component)
Trial: 21377994
Drug: Romidepsin at
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin at a dosage of 13.3 mg/m(2)/d (phase I component)
Trial: 21380781
Drug: Zoladex combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex combined with CEF chemotherapy
Trial: 21381892
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) 300 μg weekly
Trial: 21382172
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (Clopidogrel and Aspirin)
Trial: 21383285
Drug: ARQ 197
RxNorm normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ 197 at 100 to 400 mg twice per day
Trial: 21383338
Drug: Voriconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (200 mg)
Trial: 21386092
Drug: 81 mg/od
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg/od
Trial: 21386092
Drug: 81 mg/bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg/bid
Trial: 21386092
Drug: 162 mg/bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 162 mg/bid
Trial: 21386092
Drug: Aspirin dosing
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin dosing regimens
Trial: 21386997
Drug: H5N1 inactivated
RxNorm normalized name: influenza, H5N1-1203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5N1 inactivated sub-virion vaccine
Trial: 21389182
Drug: G/G genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G/G genotype with low saturated fatty acid (SFA) concentrations (below the median)
Trial: 21389182
Drug: G/G genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G/G genotype with high saturated fatty acid (SFA) concentrations (above the median)
Trial: 21389182
Drug: Minor A
RxNorm normalized name: Vinca minor extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minor A allele (G/A and A/A) with high saturated fatty acid (SFA) concentrations
Trial: 21391024
Drug: Clinician ratings
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician ratings of treatment improvement
Trial: 21393329
Drug: Deferasirox monotherapy
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox monotherapy (30-40 mg/kg/day) for 18 months
Trial: 21393334
Drug: Early discharge
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early discharge after chemotherapy completion with close outpatient follow up
Trial: 21394036
Drug: Fimasartan 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 120 mg alone
Trial: 21394036
Drug: Fimasartan 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 120 mg with Amlodipine 10 mg
Trial: 21394036
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg with Fimasartan 120 mg
Trial: 21395631
Drug: Enteric-coated cysteamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated cysteamine (mean dose 15.2 mg/kg/day) for 24 weeks
Trial: 21396809
Drug: Continuous supplemental
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous supplemental oxygen therapy
Trial: 21398104
Drug: Mometasone furoate/formoterol
RxNorm normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate/formoterol (MF/F) metered-dose inhaler (MDI) 100/10 μg with integrated dose counter, used twice daily for 4 weeks
Trial: 21398104
Drug: MF/F MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F MDI with integrated dose counter
Trial: 21398296
Drug: Panobacumab (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobacumab (1.2 mg/kg, given every 72 h)
Trial: 21398392
Drug: DNA vaccine
RxNorm normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA vaccine encoding the protein premembrane and the E glycoproteins of the NY99 strain of WNV, administered in a 3-dose regimen.
Trial: 21402043
Drug: Vaccination coverage
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination coverage for all vaccines part of the Expanded Program on Immunization (EPI)
Trial: 21402043
Drug: All recommended
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All recommended vaccines received
Trial: 21402043
Drug: Timely vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timely vaccination for measles vaccine
Trial: 21402043
Drug: Timely vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timely vaccination for Bacillus Calmette-Guérin (BCG) vaccine
Trial: 21402043
Drug: All vaccines
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All vaccines received within recommended time ranges
Trial: 21406109
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of standardized Ginkgo biloba two times per day for 12 weeks
Trial: 21406512
Drug: Antibiotic prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescription for patients producing discoloured sputum
Trial: 21406512
Drug: Antibiotic prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescription for patients producing clear/white sputum
Trial: 21406512
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for patients producing yellow sputum
Trial: 21406512
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for patients producing green sputum
Trial: 21406512
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for patients feeling unwell
Trial: 21406512
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for patients producing discoloured sputum and feeling unwell
Trial: 21410411
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for hepatitis B virus-associated membranous nephritis
Trial: 21410954
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (AL) provided by community health workers (CHWs) for unsupervised treatment at home
Trial: 21410960
Drug: Escitalopram up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram up to 50 mg
Trial: 21411559
Drug: Thyroid antibody
RxNorm normalized name: Thyroid antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid antibody positive (n=245)
Trial: 21411559
Drug: Thyroid antibody
RxNorm normalized name: Thyroid antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid antibody negative (n=3348)
Trial: 21414193
Drug: Zibotentan 10
RxNorm normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan 10 mg (single oral dose)
Trial: 21414495
Drug: Adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (80 mg at week 0, then 40 mg every other week from week 1)
Trial: 21415315
Drug: Home short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home short daily hemodialysis (SDHD) 6 times/week
Trial: 21415776
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m² (first five patients 60 mg/m²) and pemetrexed 500 mg/m² every 21 days for three cycles with chest radiotherapy to 66 Gy, followed by docetaxel 75 mg/m² every 21 days for three cycles.
Trial: 21419775
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of AS03- or MF59-adjuvanted vaccines in immunocompetent children
Trial: 21419775
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of AS03- or MF59-adjuvanted vaccines in immunocompromised children
Trial: 21425150
Drug: Clofarabine (CLO)
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine (CLO) 4 mg/m², administered as a 1-hour intravenous infusion daily for 5 days every 28 days (maximum 6 cycles)
Trial: 21425247
Drug: Novartis MF59-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novartis MF59-adjuvanted H1N1v monovalent influenza vaccine
Trial: 21426510
Drug: Hemodialysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialysis treatment with secondary hyperparathyroidism management
Trial: 21426511
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (LC) treatment, flexible daily dosage of 750-4500 mg
Trial: 21426511
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (LC) treatment
Trial: 21429209
Drug: Tissue Doppler
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue Doppler imaging systolic longitudinal ventricular velocity of the lateral wall (S'l)
Trial: 21429209
Drug: Tissue Doppler
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue Doppler imaging early diastolic longitudinal ventricular velocity of the lateral wall (E'l)
Trial: 21429209
Drug: Tissue Doppler
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue Doppler imaging late diastolic longitudinal ventricular velocity of the lateral wall (A'l)
Trial: 21429209
Drug: Glucose and
RxNorm normalized name: Glucose and treacle only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose and insulin concentrations
Trial: 21433272
Drug: Bivalirudin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/hr infusion)
Trial: 21436454
Drug: CD40 agonist
RxNorm normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD40 agonist antibody combined with gemcitabine chemotherapy
Trial: 21436454
Drug: CD40 agonist
RxNorm normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD40 agonist antibody
Trial: 21440503
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg/week and rituximab 375 mg/m(2) per week for 4 weeks, then rituximab every other 28-day cycle for a total of 12 cycles.
Trial: 21440503
Drug: Treatment-related adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related adverse events in rituximab-sensitive patients.
Trial: 21440503
Drug: Treatment-related adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related adverse events in rituximab-refractory patients.
Trial: 21441399
Drug: Single urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single urinary albumin excretion (UAE) measurement
Trial: 21441399
Drug: Albumin excretion
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin excretion rate (AER) measurement
Trial: 21444917
Drug: Prephase chemotherapy
RxNorm normalized name: estrogens, conjugated (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prephase chemotherapy followed by 3 courses of chemotherapy (for 6 patients with complete resection)
Trial: 21444917
Drug: Prephase chemotherapy
RxNorm normalized name: estrogens, conjugated (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prephase chemotherapy followed by 6 courses of chemotherapy (for 30 patients without complete resection)
Trial: 21447719
Drug: AS1409 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS1409 at 15 μg/kg weekly
Trial: 21450159
Drug: Ketamine, acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine, acute course, dosage and duration not specified
Trial: 21450573
Drug: Carvedilol at
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol at maximal tolerated dose
Trial: 21454794
Drug: Mitochondrial tRNA(Ile)
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitochondrial tRNA(Ile) 4263A>G mutation
Trial: 21454794
Drug: Mitochondrial dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitochondrial dysfunction due to 4263A>G mutation
Trial: 21454813
Drug: Intravenous dantrolene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dantrolene 1.25 mg/kg
Trial: 21454813
Drug: Intravenous dantrolene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dantrolene 2.5 mg/kg
Trial: 21455550
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg BIW for 12 weeks followed by 50 mg OW for 12 weeks
Trial: 21458098
Drug: Adiponectin to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adiponectin to homeostasis model assessment of insulin resistance (A/H ratio)
Trial: 21459588
Drug: Boron neutron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boron neutron capture therapy (BNCT) combined with fractionated X-ray irradiation and temozolomide.
Trial: 21459796
Drug: GSK461364 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK461364 administered intravenously at 300 mg (schedule A)
Trial: 21459796
Drug: GSK461364 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK461364 administered intravenously at 225 mg (schedule A)
Trial: 21459796
Drug: GSK461364 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK461364 administered intravenously at 100 mg (schedule B)
Trial: 21459796
Drug: GSK461364 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK461364 administered intravenously (both schedules)
Trial: 21459796
Drug: GSK461364 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK461364 at 225 mg (schedule A)
Trial: 21463526
Drug: Injectable risperidone
RxNorm normalized name: risperidone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable risperidone long-acting therapy (RLAT)
Trial: 21463793
Drug: Esophageal stenting
RxNorm normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esophageal stenting during neoadjuvant therapy
Trial: 21464053
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use
Trial: 21464053
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy for atrial fibrillation
Trial: 21464053
Drug: Aldosterone antagonist
RxNorm normalized name: Aldosterone antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone antagonist use
Trial: 21464155
Drug: Overall imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall imatinib treatment
Trial: 21464155
Drug: Overall sunitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall sunitinib treatment
Trial: 21464430
Drug: Methylphenidate (MPD)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPD) up to 80 mg/day
Trial: 21465636
Drug: Oral imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral imatinib at 340 mg/m²
Trial: 21467128
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no change in medication)
Trial: 21468309
Drug: Single 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 400 mg dose of albendazole (ALB)
Trial: 21470010
Drug: XRX-001 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XRX-001 vaccine (4.8 μg antigen)
Trial: 21470010
Drug: XRX-001 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XRX-001 vaccine (0.48 μg antigen)
Trial: 21470010
Drug: XRX-001 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XRX-001 vaccine (both dosages)
Trial: 21470045
Drug: etravirine (ETR)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: etravirine (ETR) 200 mg twice daily
Trial: 21471286
Drug: Gefitinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (500 mg for 5 days before surgery and continued postoperatively until recurrence)
Trial: 21471568
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of intestinal anti-TG2 antibodies
Trial: 21473790
Drug: Vorinostat in
RxNorm normalized name: Product containing vorinostat in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat in combination with pelvic palliative radiotherapy
Trial: 21473790
Drug: Vorinostat at
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat at the maximum-tolerated dose
Trial: 21474353
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose glyceryl triacetate (GTA) at 4.5 g/kg/d for 4.5 and 6 months respectively